Effects of the factor Xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice

Circulation Journal : Official Journal of the Japanese Circulation Society
Pengfei ZuoGenshan Ma

Abstract

Atherosclerosis is a progressive inflammatory disease that can lead to sudden cardiac events by plaque rupture and subsequent thrombosis. Factor Xa (FXa) not only occupies a crucial position in the coagulation cascade responsible for thrombin generation, but also has pro-inflammatory effects. The hypothesis that Fondaparinux, the selective FXa inhibitor, attenuates plaque progression and promotes stability of atherosclerotic lesions was assessed. Fondaparinux (5 mg/kg body weight/day) or 0.9% saline was intraperitoneally administered for 4 weeks to apolipoprotein E-deficient mice (n=12 per group) with established atherosclerotic lesions in the innominate arteries. Fondaparinux did not remarkably decrease the progression of atherosclerosis development in apolipoprotein E-deficient mice, but increased the thickness of fibrous cap (P=0.049) and decreased the ratio of necrotic core (P=0.001) significantly. Moreover, Fondaparinux reduced the staining against Mac-2 (P=0.017), α-SMA (P=0.002), protease-activated receptor (PAR)-1 (P=0.001), PAR-2 (P=0.003), CD-31 (P=0.024), MMP-9 (P=0.000), MMP-13(P=0.011), VCAM-1 (P=0.041) and the mRNA expression of inflammatory mediators (P<0.05) significantly, such as interleukin (IL)-6, MCP-1, IFN-...Continue Reading

References

May 23, 2001·Circulation Research·A Tedgui, Z Mallat
Dec 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carolyn MoldTerry W Du Clos
Dec 20, 2002·Nature·Peter Libby
May 30, 2003·Pharmacological Reviews·K AsadullahH D Volk
Jul 5, 2003·Blood·Diego ArdissinoPier Mannuccio Mannucci
Sep 19, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthias Girndt, Hans Kohler
Jul 21, 2004·Circulation·Zorina S Galis
Feb 11, 2005·JAMA : the Journal of the American Medical Association·Jean-Noel FiessingerUNKNOWN THRIVE Treatment Study Investigators
Aug 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ayala Hezi-YamitUma Sinha
Oct 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jason L JohnsonChristopher L Jackson
Feb 9, 2006·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Jing XiongZhenqiong Li
Mar 17, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Hannele Uusitalo-JarvinenWolfram Ruf
Aug 4, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Elena Galkina, Klaus Ley
Jul 8, 2008·Critical Care : the Official Journal of the Critical Care Forum·Toshiaki Iba, Taku Miyasho
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos
Oct 7, 2008·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Michael C Fishbein
Aug 5, 2009·The Journal of Clinical Investigation·Chris J ScottonRachel C Chambers
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Aug 11, 2010·Circulation·Julian Ilcheff BorissoffHenri M H Spronk
Jun 2, 2011·Biological & Pharmaceutical Bulletin·Ayaka SumiTakahiko Ono
Aug 30, 2011·Free Radical Biology & Medicine·Klaus JobiAnke C Rosenkranz
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Apr 14, 2012·Thrombosis Research·Eleonora Da PozzoRossella Di Stefano
Mar 9, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Shiro Uemura
Sep 13, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Daiju Fukuda, Masanori Aikawa
Jan 31, 2014·Current Atherosclerosis Reports·Robert S Fenning, Robert L Wilensky

❮ Previous
Next ❯

Citations

Oct 9, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Julian FriebelUrsula Rauch
Mar 1, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Atsushi OkadaUNKNOWN NaDEF Investigators
Dec 8, 2016·Journal of Cellular Physiology·Safieh EbrahimiSeyed Mahdi Hassanian
Feb 8, 2018·Current Vascular Pharmacology·Andrej Fabjan, Fajko F Bajrović
Aug 28, 2019·International Journal of Molecular Sciences·Yuki NaritaKenichiro Kitamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.